Advertisement

AAPS PharmSciTech

, Volume 18, Issue 1, pp 156–165 | Cite as

Decorporation of Iron Metal Using Dialdehyde Cellulose-Deferoxamine Microcarrier

  • Priyanka TyagiEmail author
  • Amit Kumar
  • Dikshi Gupta
  • Harpal Singh
Research Article

ABSTRACT

Deferoxamine iron chelator has a limited therapeutic index due to rapid clearance from blood and possesses dose-limiting toxicity. Therefore, an intravenous deferoxamine delivery system based on dialdehyde cellulose (DAC) polymer was developed and its efficacy and toxicity were tested in iron-overloaded animals. The amino groups of deferoxamine were conjugated to free aldehyde moieties of dialdehyde cellulose via Schiff base reaction to form dialdehyde cellulose-deferoxamine (DAC-DFO) conjugate and characterized by Fourier transform infrared spectrophotometer, scanning electron microscope, and X-ray diffraction. The toxicity of prepared formulation was analyzed by XTT cell viability assay and LD50 study in mice. The change in serum iron levels, after intravenous administration of formulation, was observed in iron-overloaded rats. The DAC-DFO conjugate was tagged with Tc-99m to study the blood kinetics and observe change in blood circulation time. DAC-DFO conjugate was dispersible in water at concentration ∼75 mg/ml. In vitro cytotoxicity assay and LD50 study in mice indicated significantly enhanced safety of covalently bound deferoxamine (at >1000 mg/kg body weight compared to free drug at ∼270 mg/kg dose). A preliminary scintigraphy imaging and blood clearance study, with technetium-99m, indicated prolonged circulation of conjugated DFO in rabbit blood. A single dose of formulation injected into iron overloaded animals was found to maintain the normal serum iron levels until 10 days. The polymeric conjugate was effective in maintaining normal serum iron levels until 10 days at a dose of 100 mg/kg body weight.

KEY WORDS

deferoxamine dialdehyde cellulose iron chelation iron decorporation iron overload 

Notes

ACKNOWLEDGMENTS

The authors gratefully acknowledge the Department of Science and Technology (DST), India, for providing funds to carry out the research work. The authors are also thankful to Dr. R. P. Tripathi, Director, Institute of Nuclear Medicine & Allied Sciences (INMAS), DRDO, Delhi, India, for providing animal facility and scintigraphy studies.

COMPLIANCE WITH ETHICAL STANDARDS

The authors are responsible for the content and writing of the paper. The study protocol was reviewed and approved by the Institutional Animal Ethics Committee of INMAS.

Conflict of Interest

The authors declare that there are no competing interests.

REFERENCES

  1. 1.
    Dallman PR. Biochemical basis for the manifestations of iron deficiency. Annu Rev Nutr. 1986;6:13–40.CrossRefPubMedGoogle Scholar
  2. 2.
    Wikstrom M, Babcock GT. Oxygen activation and the conservation of energy in cell respiration. Nature. 1992;356:301–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999;341:1986–95.CrossRefPubMedGoogle Scholar
  4. 4.
    Bothwell TH, MacPhail AP. Hereditary hemochromatosis: etiologic, pathologic, and clinical aspects. Semin Hematol. 1998;35:55–71.PubMedGoogle Scholar
  5. 5.
    Fairweather-Tait SJ. Iron absorption in male C282Y heterozygotes. Am J Clin Nutr. 2005;81:814–21.PubMedGoogle Scholar
  6. 6.
    Gutteridge JMC, Richmond R, Halliwell B. Inhibition of the iron-catalyzed formation of hydroxyl radicals from superoxide and of lipid peroxidation by desferrioxamine. Biochem J. 1979;184:469–72.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Toyokuni S. Iron-induced carcinogenesis: the role of redox regulation. Free Radic Biol Med. 1996;20:553–66.CrossRefPubMedGoogle Scholar
  8. 8.
    Okada S. Iron-induced tissue damage and cancer: the role of reactive oxygen species-free radicals. Pathol Int. 1996;46:311–32.CrossRefPubMedGoogle Scholar
  9. 9.
    Bartfay WJ, Bartfay E. Iron-overload cardiomyopathy: evidence for a free radical—mediated mechanism of injury and dysfunction in a murine model. Biol Res Nurs. 2000;2:49–59.CrossRefPubMedGoogle Scholar
  10. 10.
    Gholson CF, Provenza JM, Bacon BR. Hepatologic considerations in patients with parenchymal liver disease undergoing surgery. Am J Gastroenterol. 1990;85:487–96.PubMedGoogle Scholar
  11. 11.
    Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard BG. Hemochromatosis mutations in the general population: iron overload progression rate. Blood. 2004;103:2914–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Kordas K, Stoltzfus RJ. New evidence of iron and zinc interplay at the enterocyte and neural tissues. J Nutr. 2004;134:1295–8.PubMedGoogle Scholar
  13. 13.
    Hill CH, Matrone G. Chemical parameters in the study of in vivo and in vitro interactions of transition elements. Fed Proc. 1970;29:1474–81.PubMedGoogle Scholar
  14. 14.
    Antle EA. Who needs a therapeutic phlebotomy? Clin J Oncol Nurs. 2010;14:694–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Jurkevitch E, Hadar Y, Chen Y, Libman J, Shanzer A. Iron uptake and molecular recognition in pseudomonas putida: receptor mapping with ferrichrome and its biomimetic analogs. J Bacterial. 1992;174:78–83.CrossRefGoogle Scholar
  16. 16.
    Reid RT, Live DH, Faulkner DJ, Butler A. A siderophore from a marine bacterium with an exceptional ferric ion affinity constant. Nature. 1993;366:455–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Tufano TP, Pecoraro VL, Raymond KN. Ferric ion sequestering agents: kinetics of iron release from ferritin to catechoylamides. Biochim Biophys Acta. 1981;668:420–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Kontoghiorghes GJ, Evans RW. Site specificity of iron removal from transferrin by α-ketohydroxypyridine chelators. FEBS Lett. 1985;189:141–4.CrossRefPubMedGoogle Scholar
  19. 19.
    Hershko C. Determinants of fecal and urinary iron excretion in desferrioxamine-treated rats. Blood. 1978;51:415–23.PubMedGoogle Scholar
  20. 20.
    Westlin WF. Deferoxamine as a chelating agent. Clin Toxicol. 1971;4:597–602.CrossRefPubMedGoogle Scholar
  21. 21.
    Summers MR, Jacobs A, Tudway D, Perera P, Ricketts C. Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br J Haematol. 1979;42:547–55.CrossRefPubMedGoogle Scholar
  22. 22.
    Olivieri NF, Brittenham GM. Iron chelation therapy and the treatment of thalassemia. Blood. 1997;89:739–61.PubMedGoogle Scholar
  23. 23.
    Wong B, Richardson DR. Beta-thalassaemia: emergence of new and improved iron chelators for treatment. Int J Biochem Cell Biol. 2003;35:1144–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Hallaway PE, Eaton JW, Panter SS, Hedlund BE. Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers. Proc Natl Acad Sci. 1989;86:10108–12.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Singh M, Ray AR, Vasudevan P, Verma K, Guha SK. Potential biosoluble carriers: biocompatibility and biodegradability of oxidized cellulose. Biomater Med Devices Artif Organs. 1979;7:495–512.CrossRefPubMedGoogle Scholar
  26. 26.
    Mousa SA, Ritger RC, Smith RD. Efficacy and safety of deferoxamine conjugated to hydroxyethyl starch. J Cardiovasc Pharmacol. 1992;19:425–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Devi KS, Sinha TJM, Vasudeven P. Biosoluble surgical material from 2.3-dialdehyde cellulose. Biomaterials. 1986;7:193–6.CrossRefGoogle Scholar
  28. 28.
    Mester L. The formazan reaction in proving the structure of periodate oxidized polysaccharides. J Am Chem Soc. 1955;77:5452–3.CrossRefGoogle Scholar
  29. 29.
    Kim UJ, Wada M, Kuga S. Solubilization of dialdehyde cellulose by hot water. Carbohydr Polym. 2004;56:7–10.CrossRefGoogle Scholar
  30. 30.
    Veelaert S, de Wit D, Gotlieb KF, Verhe R. Chemical and physical transitions of periodate oxidized potato starch in water. Carbohydr Polym. 1997;33:153–62.CrossRefGoogle Scholar
  31. 31.
    Iyer G, Pinaud F, Xu J, Ebenstein Y, Li J, Chang J, et al. Aromatic aldehyde and hydrazine activated peptide coated quantum dots for easy bioconjugation and live cell imaging. Bioconjug Chem. 2011;22:1006–11.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Singh M, Ray A, Vasudevan P. Biodegradation studies on periodate oxidized cellulose. Biomaterials. 1982;3:16–20.CrossRefPubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2016

Authors and Affiliations

  • Priyanka Tyagi
    • 1
    Email author
  • Amit Kumar
    • 2
  • Dikshi Gupta
    • 1
  • Harpal Singh
    • 1
  1. 1.Center for Biomedical EngineeringIndian Institute of TechnologyDelhiIndia
  2. 2.Department of Nuclear MedicineInstitute of Nuclear Medicine & Allied Sciences (INMAS), DRDODelhiIndia

Personalised recommendations